Table 1.

Main baseline features of the 13 patients meeting ASAS criteria [30] for axial spondyloarthritis

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
Type of SpA	AS	AS	AS	AS	AS	AS	AS
Sacroiliitis	Grade 4	Grade 4	Grade 3	Grade 4	Grade 3	Grade 3	Grade 4
HLA-B27	+	+	+	+	+	+	+
Gender	Female	Female	Female	Male	Male	Female	Male
Disease duration (years)	9	27	11	6	4	24	19
Main location of inflammatory pain	Back, neck, chest, peripheral enthesitis (Achilles tendon, knee)	Neck, chest, peripheral enthesitisa	Back, buttock, chest	Neck	Back, neck, buttock	Back, neck, chest	Back, neck, peripheral enthesitis (Achilles tendon)
Concomitant NSAIDs/steroids (dosage)	Yes/no	Yes/no	Yes/no	No/no	No/no	Yes/no	Yes/no
Concomitant DMARDs	No	No	No	Sulfasalazine	No	No	No
Previous biologics other than anti-TNF	Abatacept	Abatacept	Abatacept	No	No	No	No
	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12	Patient 13
Type of SpA	AS and PsA	uSpA	uSpA	uSpA	uSpA	uSpA
Sacroiliitis	Grade 3	Grade 1	Grade 0	Grade 0	Grade 0	Grade 0
HLA-B27	-	+	+	+	+	+
Gender	Male	Female	Female	Male	Female	Male
Disease duration (years)	15	11	9	25	6	12
Main location of inflammatory pain	Back, neck, arthritis	Back, neck, buttock, chest	Back, buttock	Back, neck, buttock	Back, buttock, chest, peripheral enthesitis (Achilles tendon)	Back, neck
Concomitant NSAIDs/steroids (dosage)	No/no	Yes/no	Yes/no	No/no	Yes/no	No/yes (25 mg/day)
Concomitant DMARDs	No	No	No	No	No	No
Previous biologics other than anti-TNF	Rituximab	Abatacept	Abatacept	No	No	No

AS, ankylosing spondylitis meeting modified New York criteria [33]; ASAS, Assessment of SpondyloArthritis International Society; DMARD, disease-modifying antirheumatic drug; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis meeting Classification Criteria for Psoriatic Arthritis [36]; SpA, spondyloarthritis; uSpA, undifferentiated spondyloarthritis. ^aLocation unknown.